HuGE Literature Finder
Records
1
-
17
| Personalized Medicine in Infant Population with Cancer: Pharmacogenetic Pilot Study of Polymorphisms Related to Toxicity and Response to Chemotherapy. Cancers 2023 3 15 (5): . Urtasun Andrea, Olivera Gladys G, Sendra Luis, Aliño Salvador F, Berlanga Pablo, Gargallo Pablo, Hervás David, Balaguer Julia, Juan-Ribelles Antonio, Andrés María Del Mar, Cañete Adela, Herrero María Jo |
| DNA methylation inhibition in myeloma: Experience from a phase 1b study of low-dose continuous azacitidine in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. Seminars in hematology 2021 1 58 (1): 45-55. Khouri Jack, Faiman Beth M, Grabowski Dale, Mahfouz Reda Z, Khan Shahper N, Wei Wei, Valent Jason, Dean Robert, Samaras Christy, Jha Babal K, Lazarus Hillard, Campagnaro Erica L, Malek Ehsan, Reed Janice, Karam Mary Ann, Hamilton Kimberly, Fada Sherry, Kalaycio Matt, Liu Hien, Sobecks Ronald, Saunthararajah Yogen, Chew Yap, Orloff Mohammed, Reu Frederic |
| Gene-Gene Interactions of Gemcitabine Metabolizing-Enzyme Genes hCNT3 and WEE1 for Preventing Severe Gemcitabine-Induced Hematological Toxicity. Journal of clinical pharmacology 2021 5 61 (10): 1376-1385. Li Juan, Chen Bing, Xi Wen-Qi, Yang Chen, Zhang Wei-X |
| Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). ESMO open 2020 Dec 6 (1): 100019. Pellegrino B, Cavanna L, Boggiani D, Zamagni C, Frassoldati A, Schirone A, Caldara A, Rocca A, Gori S, Piacentini F, Berardi R, Brandes A A, Foglietta J, Villa F, Todeschini R, Tognetto M, Naldi N, Bortesi B, Montemurro F, Ardizzoni A, Boni L, Musolino |
An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance).
Pharmacogenetics and genomics 2019 Mar . Innocenti Federico, Jiang Chen, Sibley Alexander B, Denning Stefanie, Etheridge Amy S, Watson Dorothy, Niedzwiecki Donna, Hatch Ace J, Hurwitz Herbert I, Nixon Andrew B, Furukawa Yoichi, Kubo Michiaki, Crona Daniel J, Kindler Hedy L, McLeod Howard L, Ratain Mark J, Owzar Kour |
| Cytidine deaminase polymorphism predicts toxicity of gemcitabine-based chemotherapy. Gene 2015 Mar 559 (1): 31-7. Ding Xiangxiang, Chen Wenwei, Fan Haijian, Zhu B |
| High incidence of severe neutropenia after gemcitabine-based chemotherapy in Chinese cancer patients with CDA 79A>C mutation. Clinica chimica acta; international journal of clinical chemistry 2012 Aug 413 (15-16): 1284-7. Xu Jialin, Zhou Yuhong, Zhang Jing, Chen Yuancheng, Zhuang Rongyuan, Liu Tianshu, Cai Weim |
| A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research. Investigational new drugs 2012 Jun 30 (3): 1164-74. Oh Do-Youn, Lee Keun Wook, Lee Kyung-Hee, Sohn Chang-Hak, Park Young Suk, Zang Dae Young, Ryoo Hun-Mo, Song Hong-Suk, Kim Jin-Soo, Kang Hye-Jin, Kim Bong-Seog, Bang Yung-J |
| Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine. Cancer chemotherapy and pharmacology 2011 May . Joerger M, Burgers JA, Baas P, Doodeman VD, Smits PH, Jansen RS, Vainchtein LD, Rosing H, Huitema AD, Beijnen JH, Schellens JH |
| [Pharmacogenomic research for avoiding adverse reactions by anti-cancer drugs]. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 2011 Feb 131 (2): 239-46. Saito Yoshi |
| Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer. Cancer 2010 Nov 116 (22): 5325-35. Tanaka Motofumi, Javle Milind, Dong Xiaoqun, Eng Cathy, Abbruzzese James L, Li Dongh |
| Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms. Clinical pharmacokinetics 2010 Aug 49 (8): 549-58. Sugiyama Emiko, Kaniwa Nahoko, Kim Su-Ryang, Hasegawa Ryuichi, Saito Yoshiro, Ueno Hideki, Okusaka Takuji, Ikeda Masafumi, Morizane Chigusa, Kondo Shunsuke, Yamamoto Noboru, Tamura Tomohide, Furuse Junji, Ishii Hiroshi, Yoshida Teruhiko, Saijo Nagahiro, Sawada Jun-Ic |
| Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity. Clinical cancer research : an official journal of the American Association for Cancer Research 2010 Jan 16 (1): 320-9. Okazaki Taro, Javle Milind, Tanaka Motofumi, Abbruzzese James L, Li Dongh |
| Distribution of gemcitabine pathway genotypes in ethnic Asians and their association with outcome in non-small cell lung cancer patients. Lung cancer (Amsterdam, Netherlands) 2009 Jan 63 (1): 121-7. Soo Ross A, Wang Ling Zhi, Ng Swee Siang, Chong Pei Yi, Yong Wei Peng, Lee Soo Chin, Liu Jian Jun, Choo Tai Bee, Tham Lai San, Lee How Sung, Goh Boon Cher, Soong Rich |
| Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clinical cancer research : an official journal of the American Association for Cancer Research 2008 Mar 14 (6): 1797-803. Tibaldi Carmelo, Giovannetti Elisa, Vasile Enrico, Mey Valentina, Laan Adrie C, Nannizzi Sara, Di Marsico Roberta, Antonuzzo Andrea, Orlandini Cinzia, Ricciardi Simona, Del Tacca Mario, Peters Godefridus J, Falcone Alfredo, Danesi Roma |
| Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007 Jan 25 (1): 32-42. Sugiyama E, Kaniwa N, Kim SR, Kikura-Hanajiri R, Hasegawa R, Maekawa K, Saito Y, Ozawa S, Sawada J, Kamatani N, Furuse J, Ishii H, Yoshida T, Ueno H, Okusaka T, Saijo N |
| The impact of CDA A79C gene polymorphisms on the response and hematologic toxicity in gemcitabine-treated patients: a meta-analysis. The International journal of biological markers 0 29 (3): e224-32. Li Hui, Wang Xiangling, Wang Xiuw |
- Page last reviewed:Feb 1, 2023
- Page last updated:Mar 22, 2023
- Content source: